Glaukos Corporation (GKOS) Tops Q3 EPS by 39c

Glaukos Corporation (NYSE: GKOS) reported Q3 EPS of ($0.09), $0.39 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $31.5 million versus the consensus estimate of $53.75 million.

“Our solid third quarter performance reflects our teams’ unwavering commitment to advance our key strategic priorities and execute our plans despite the unique challenges associated with the ongoing COVID-19 pandemic,” said Thomas Burns, Glaukos president and chief executive officer. “We remain focused on the near and long-term fundamental growth prospects of our business as we advance our mission to create a strategic vision care leader with disruptive franchises in glaucoma, corneal health and retinal disease that provide sustainable solutions to important clinical needs.”

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'